



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

22<sup>nd</sup> April 2024

To,

**BSE LIMITED**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India  
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received an Order dated 20<sup>th</sup> April 2024 from Jammu & Kashmir GST (State Tax) authorities, disallowing certain GST credits in Jammu & Kashmir Union Territory. The relevant details to be disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	State Taxes Officer Circle L-Jammu, Jammu and Kashmir
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 20 <sup>th</sup> April 2024 passed under Section 73 of CGST Act, 2017 for Tax of Rs.70,252 along with Interest of Rs 63,226 and Penalty of Rs.20,000, aggregating to demand of Rs.1,53,478 for FY18-19 in Jammu & Kashmir Union Territory
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	20 <sup>th</sup> April 2024
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has disallowed certain GST credit and raised GST demand for FY 2018-19 on account of difference in GST credit mismatch between Company's GST returns and details reported by vendors in their GST returns.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on GSK. The Company is evaluating the said demand and possible options under GST Law going forward

Note – The said demand Order has been received by the Company on 20<sup>th</sup> April 2024, i.e. on Saturday evening due to which, the above disclosure is being made today.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151